Clinical Trial: Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Study Status: Completed
Recruit Status: RECRUITING
Condition: Solid Tumor
Study Type: INTERVENTIONAL
Official Title: A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGF?R Serine/Threonine Kinase Inhibitor, Administered in Combination With Pembrolizuma
Brief Summary:
This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.The main purpose of phase 1b is to determine the RP2DC of TU2218 and Pembrolizumab while the main purpose of phase 2a is to evaluate the antitumor efficacy of TU2218 in combination with Pembrolizumab in 3 different selected tumor type cohorts.
Read more